Supportive therapies for myeloid leukemia including blood transfusion and growth factors

Hisayuki Yao, Eishi Ashihara, Taira Maekawa

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Bone marrow suppression after intensive chemotherapies in patients with myeloid leukemia is severe, resulting in the reduction of the number of white blood cells, red blood cells, and platelets. Supportive therapies are indispensable for the management of these leukemia patients. The improvement of blood cell transfusion can decrease side effects of chemotherapies and establish the safety. But we still have notable side effects of transfusion such as TRALI (transfusion-related acute lung injury), platelet immunologic refractory state, and so on. Cytokine therapy especially with G-CSF (granulocyte colony-stimulating factor) administration, changed the treatment of myeloid leukemia. G-CSF can shorten the duration of neutropenia and decrease the risk of infection. Recently the effects of Epo (erythropoietin) on chemotherapy-induced anemia have been demonstrated. We discuss here the indications of blood cell transfusion and cytokine therapies in the treatment for myeloid leukemia.

Original languageEnglish
Pages (from-to)1951-1957
Number of pages7
JournalNippon rinsho. Japanese journal of clinical medicine
Volume67
Issue number10
Publication statusPublished - Jan 1 2009
Externally publishedYes

Fingerprint

Myeloid Leukemia
Blood Transfusion
Intercellular Signaling Peptides and Proteins
Granulocyte Colony-Stimulating Factor
Drug Therapy
Blood Cells
Blood Platelets
Cytokines
Therapeutics
Acute Lung Injury
Erythropoietin
Neutropenia
Anemia
Leukemia
Leukocytes
Erythrocytes
Bone Marrow
Safety
Infection

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Supportive therapies for myeloid leukemia including blood transfusion and growth factors. / Yao, Hisayuki; Ashihara, Eishi; Maekawa, Taira.

In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 67, No. 10, 01.01.2009, p. 1951-1957.

Research output: Contribution to journalReview article

@article{aa5f4208ef8241c7aaa0ae017de5a6f6,
title = "Supportive therapies for myeloid leukemia including blood transfusion and growth factors",
abstract = "Bone marrow suppression after intensive chemotherapies in patients with myeloid leukemia is severe, resulting in the reduction of the number of white blood cells, red blood cells, and platelets. Supportive therapies are indispensable for the management of these leukemia patients. The improvement of blood cell transfusion can decrease side effects of chemotherapies and establish the safety. But we still have notable side effects of transfusion such as TRALI (transfusion-related acute lung injury), platelet immunologic refractory state, and so on. Cytokine therapy especially with G-CSF (granulocyte colony-stimulating factor) administration, changed the treatment of myeloid leukemia. G-CSF can shorten the duration of neutropenia and decrease the risk of infection. Recently the effects of Epo (erythropoietin) on chemotherapy-induced anemia have been demonstrated. We discuss here the indications of blood cell transfusion and cytokine therapies in the treatment for myeloid leukemia.",
author = "Hisayuki Yao and Eishi Ashihara and Taira Maekawa",
year = "2009",
month = "1",
day = "1",
language = "English",
volume = "67",
pages = "1951--1957",
journal = "Astrophysical Journal",
issn = "0004-637X",
publisher = "IOP Publishing Ltd.",
number = "10",

}

TY - JOUR

T1 - Supportive therapies for myeloid leukemia including blood transfusion and growth factors

AU - Yao, Hisayuki

AU - Ashihara, Eishi

AU - Maekawa, Taira

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Bone marrow suppression after intensive chemotherapies in patients with myeloid leukemia is severe, resulting in the reduction of the number of white blood cells, red blood cells, and platelets. Supportive therapies are indispensable for the management of these leukemia patients. The improvement of blood cell transfusion can decrease side effects of chemotherapies and establish the safety. But we still have notable side effects of transfusion such as TRALI (transfusion-related acute lung injury), platelet immunologic refractory state, and so on. Cytokine therapy especially with G-CSF (granulocyte colony-stimulating factor) administration, changed the treatment of myeloid leukemia. G-CSF can shorten the duration of neutropenia and decrease the risk of infection. Recently the effects of Epo (erythropoietin) on chemotherapy-induced anemia have been demonstrated. We discuss here the indications of blood cell transfusion and cytokine therapies in the treatment for myeloid leukemia.

AB - Bone marrow suppression after intensive chemotherapies in patients with myeloid leukemia is severe, resulting in the reduction of the number of white blood cells, red blood cells, and platelets. Supportive therapies are indispensable for the management of these leukemia patients. The improvement of blood cell transfusion can decrease side effects of chemotherapies and establish the safety. But we still have notable side effects of transfusion such as TRALI (transfusion-related acute lung injury), platelet immunologic refractory state, and so on. Cytokine therapy especially with G-CSF (granulocyte colony-stimulating factor) administration, changed the treatment of myeloid leukemia. G-CSF can shorten the duration of neutropenia and decrease the risk of infection. Recently the effects of Epo (erythropoietin) on chemotherapy-induced anemia have been demonstrated. We discuss here the indications of blood cell transfusion and cytokine therapies in the treatment for myeloid leukemia.

UR - http://www.scopus.com/inward/record.url?scp=73449084161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73449084161&partnerID=8YFLogxK

M3 - Review article

C2 - 19860196

AN - SCOPUS:73449084161

VL - 67

SP - 1951

EP - 1957

JO - Astrophysical Journal

JF - Astrophysical Journal

SN - 0004-637X

IS - 10

ER -